Publication

Article

CURE

Winter 2013
Volume12
Issue 4

Reel Recovery Retreats

Author(s):

Jon Garinn

Reel Recovery offers free fly-fishing retreats for men recovering from cancer.

For men who have cancer, talking about their disease can sometimes be a challenge. That’s why Reel Recovery offers free fly-fishing retreats for men recovering from all forms of cancer. For more than a decade, the nonprofit organization has combined expert fly-fishing instruction with directed conversations, giving participants time to share their stories, learn a new skill and form friendships. To learn more about the 2014 retreat lineup, visit reelrecovery.org.

Articles in this issue
Changing Course in Pancreatic Cancer
Message From the Editor
Dose of Reality Effective at Stopping Smokers
Michael Douglas Reveals He Had Tongue Cancer
Studies Confirm Effectiveness of Colorectal Cancer Screening
Reel Recovery Retreats
Dispatch: Society for Integrative Oncology's 10th Annual Meeting
Poor Kidney Function a Possibility in Adult Survivors of Childhood Cancer
Personalized Medicine Should Include High-Quality, High-Value Care
How I Lost My Uterus and Found My Voice
Why Observing Treatment Milestones is an Individual Decision
For Caregivers: Tips Before Planning that "End of Treatment" Party
Solving the Treatment Resistance Riddle
Advances in Screening & Early Detection of Pancreatic Cancer
Post-Mastectomy Pain Hits a Nerve
Related Videos
Image of man with black hair.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of man with brown and grey hair.
Dr. Kelly Stratton
Reginald Tucker-Seeley, MA, ScM, ScD, an expert on prostate cancer
Related Content
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
February 16th 2025

EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer

Roman Fabbricatore
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
"Prostate cancer" text.
February 14th 2025

Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer

Alex Biese
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months. | © pikovit - stock.adobe.com
February 13th 2025

Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT

Alex Biese
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.
Illustration of body highlighting prostate area.
February 13th 2025

Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer

Ryan Scott
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.